Algert Global LLC Has $2.16 Million Stock Position in Progyny, Inc. (NASDAQ:PGNY)

Algert Global LLC lessened its stake in shares of Progyny, Inc. (NASDAQ:PGNY) by 32.4% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 124,937 shares of the company’s stock after selling 59,948 shares during the period. Algert Global LLC’s holdings in Progyny were worth $2,155,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Signaturefd LLC raised its stake in shares of Progyny by 1,355.0% during the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company’s stock worth $25,000 after purchasing an additional 1,355 shares in the last quarter. GAMMA Investing LLC raised its position in Progyny by 341.4% during the fourth quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock worth $28,000 after acquiring an additional 1,246 shares in the last quarter. Nisa Investment Advisors LLC lifted its stake in Progyny by 108.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company’s stock valued at $51,000 after acquiring an additional 1,526 shares during the last quarter. Caitlin John LLC grew its position in shares of Progyny by 2,974.8% in the 4th quarter. Caitlin John LLC now owns 3,290 shares of the company’s stock valued at $57,000 after acquiring an additional 3,183 shares during the period. Finally, Natixis acquired a new position in shares of Progyny during the 4th quarter worth about $69,000. 94.93% of the stock is owned by institutional investors and hedge funds.

Progyny Stock Performance

Shares of Progyny stock opened at $23.40 on Friday. The firm has a 50-day moving average of $21.96 and a 200-day moving average of $19.47. Progyny, Inc. has a 52-week low of $13.39 and a 52-week high of $32.57. The stock has a market cap of $2.00 billion, a PE ratio of 40.34, a PEG ratio of 2.39 and a beta of 1.37.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.45 by ($0.28). Progyny had a net margin of 5.03% and a return on equity of 11.36%. During the same quarter in the prior year, the company posted $0.17 earnings per share. The business’s revenue was up 16.5% compared to the same quarter last year. Equities research analysts predict that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. BTIG Research upgraded shares of Progyny from a “neutral” rating to a “buy” rating and set a $28.00 target price for the company in a research note on Monday, March 31st. Canaccord Genuity Group raised their price objective on Progyny from $17.00 to $23.00 and gave the company a “hold” rating in a research report on Friday, February 28th. JPMorgan Chase & Co. boosted their target price on Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a report on Tuesday, January 28th. Finally, Bank of America raised their price target on Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, February 11th. Eight investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Progyny currently has a consensus rating of “Hold” and an average price target of $23.64.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.